Source:http://linkedlifedata.com/resource/pubmed/id/11137572
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2001-1-26
|
pubmed:abstractText |
The damage of acetylcholine receptor (AChR) at neuromuscular junctions of experimental autoimmune myasthenia gravis (EAMG), an animal model of human MG, is mediated by B cells which require T cell help. The Th2 associated cytokine IL-10 suppresses production of cytokines released by Th1 cells and is considered for treatment of human autoimmune diseases. To evaluate the role of IL-10 in EAMG, rhIL-10 was administered daily to Lewis rats by the subcutaneous route starting at the day of immunization and continued for 7 weeks. IL-10 failed to abrogate EAMG at low dose (0.1 or 1 microg/day) and at the dose of 3 microg/day caused earlier onset and aggravated clinical signs of EAMG when compared to EAMG rats injected with PBS only. Although Th1 responses reflected by AChR-induced lymphocyte proliferation and levels of IFN-gamma secreting cells, as well as AChR-induced Th1 cytokine mRNA expression was suppressed, augmented IL-4 mRNA expression and AChR-specific B cell responses may play an important role in the failure of IL-10 to abrogate EAMG. This study implicates a critical precaution in planning immunotherapy of IL-10 in antibody-mediated autoimmune diseases, e.g. MG.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Acetylcholine,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-10,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cholinergic
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
0165-5728
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
113
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
10-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:11137572-Acetylcholine,
pubmed-meshheading:11137572-Animals,
pubmed-meshheading:11137572-B-Lymphocytes,
pubmed-meshheading:11137572-Cell Division,
pubmed-meshheading:11137572-Female,
pubmed-meshheading:11137572-Gene Expression,
pubmed-meshheading:11137572-Humans,
pubmed-meshheading:11137572-Immunoglobulin G,
pubmed-meshheading:11137572-Interleukin-10,
pubmed-meshheading:11137572-Muscle Weakness,
pubmed-meshheading:11137572-Myasthenia Gravis, Autoimmune, Experimental,
pubmed-meshheading:11137572-RNA, Messenger,
pubmed-meshheading:11137572-Rats,
pubmed-meshheading:11137572-Rats, Inbred Lew,
pubmed-meshheading:11137572-Receptors, Cholinergic,
pubmed-meshheading:11137572-Th2 Cells,
pubmed-meshheading:11137572-Torpedo
|
pubmed:year |
2001
|
pubmed:articleTitle |
Interleukin 10 aggravates experimental autoimmune myasthenia gravis through inducing Th2 and B cell responses to AChR.
|
pubmed:affiliation |
Experimental Neuroimmunology Unit, Division of Neurology, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|